ISO 20916
International standard for Good Study Practice for clinical performance studies of IVDs using specimens from human subjects.
Definition
ISO 20916 is the IVD analogue to ISO 14155 - defining responsibilities, design, conduct, recording, and reporting of IVD clinical performance studies. EU IVDR Annex XIII references it as state of the art. The 2019 edition covers study planning, ethics committee review, informed consent, conduct, monitoring, data management and reporting for studies using specimens from human subjects. It is widely used to support the performance study requirements in IVDR Articles 57 to 77.What this means in practice
Required reading for any IVD sponsor designing performance studies under IVDR; closes a long-standing gap in IVD-specific GCP guidance.Examples
- A manufacturer of a new immunoassay for a disease biomarker designs a clinical performance study following ISO 20916 to gather data on diagnostic sensitivity and specificity.
- An IVD company developing a molecular diagnostic test for an infectious agent uses ISO 20916 as a guide to establish ethical considerations and informed consent processes for their study participants.
- A regulatory body reviews a manufacturer's clinical performance study report for a novel IVD device, specifically assessing adherence to the data integrity and reporting requirements outlined in ISO 20916 clause 7.
- •Confusing ISO 20916 requirements with those of ISO 14155, which applies to non-IVD medical devices.
- •Failing to establish a comprehensive clinical performance study plan as required by ISO 20916 clause 5.2.
- •Neglecting to appoint a qualified principal investigator and clearly define their responsibilities according to ISO 20916 clause 4.2.
- •Not adequately documenting adverse events and their causality assessment during an IVD clinical performance study.
- •Applying ISO 20916 retrospectively to studies initiated before its publication without a clear justification or transition plan.
Frequently asked questions
Related terms
Grouped by themeEditor's picks
· Hand-selected related conceptsMore in Regulatory
· Same categoryFDA submission demonstrating a device is substantially equivalent to a legally marketed predicate.
Two alternative disclosure mechanisms in a 510(k) submission, a Summary is public on FDA's website; a Statement promises to share Safety & Effectiveness info on request.
Formal mechanism to ask FDA whether a product is a device and, if so, its likely classification.
510(k) variant that relies on FDA guidance, special controls, or recognized consensus standards.
Where this term appears across MedTech Terms.
Latest in MedTech
Sources
3 sourcesSources support the definition or relevant regulatory context, not necessarily every claim on this page. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.
- 1ISO 20916Tier 1 VerifiedISOiso.org
- 2FDA - Medical DevicesTier 2 VerifiedFDAfda.gov
- 3European Commission - Medical DevicesTier 2 VerifiedEuropean Commissionhealth.ec.europa.eu
Inline markers like [1] jump to the matching reference above.